Douglas S. Harrington, MD, FASCP, FCAP

  • Has helped bring more than 200 discoveries into clinical use. 
  • Board Certified in Clinical Pathology, Anatomic Pathology and Hematology. 
  • During his post-secondary education, he received the George B. Packard Award for Outstanding Achievement in Surgery, was asked to join Phi Beta Kappa(and Alpha Epsilon Delta), and received a citation for academic excellence, a scholarship, a grant, and a student research fellowship.

Detailed Resumé

Douglas Harrington has been involved in the research, development and translation of more than 200 discoveries into clinical use.  He is the inventor of the Smart Vascular DxTM Test, a breakthrough blood test for the detection of vascular inflammation (the leading cause of heart attacks, which was unknown previous to his discovery of it), metabolic syndromes, autoimmune diseases and cancer.  His technology (formerly called the Protein Unstable Lesion Signature, or PULS, Cardiac Test) was the recipient of the 2016 ABL Grand Prize Award forInnovation in Healthcare.  Harrington has authored and published numerous peer-reviewed papers, developed multiple patents and taken a number of new molecular technologies through state and federal regulatory approval. He is an expert in laboratory diagnostic testing and is a renowned speaker, panelist and lecturer in the areas of preventive medicine and technology development.

Education & Training

  • BA in Molecular Biology - University of Colorado 
  • Phi Beta Kappa
  • Alpha Epsilon Delta
  • Grant and Scholarship
  • Student Research Fellowship, 1976
  • Doctorate of Medicine (MD) - University of Colorado School of Medicine
  • Citation for Academic Excellence
  • George B. Packard Award for Outstanding Achievement in Surgery
  • Residency, Surgery - University of Arizona College of Medicine, Tucson 
  • Residency, Pathology–Anatomic & Clinical - University of Colorado Anschutz Medical Campus
  • Fellowship, Hematopathology - University of Nebraska College of Medicine

Board Certifications

  • Clinical Pathology - American Board of Pathology
  • Anatomic Pathology - American Board of Pathology
  • Hematology - American Board of Internal Medicine


  • The American Society for Clinical Pathology 
  • The College of American Pathologists

Since he received his MD in 1978, Dr. Harrington has had the opportunity of being: 

  • A resident member of one of the first heart transplant teams (led by Dr. Jack Copeland), 
  • co-founder of one of the first clinical molecular biology laboratories in the U.S. with the Nebraska Lymphoma Study Group (headed by Dr. Jim Armitage), 
  • co-founder and CEO of the team that developed one of the first FDA approved digital microscopes targeted at minimal residual disease and circulating tumor cells, 
  • a member of both the Scientific Advisory Board and the Board of Directors of the Orange County chapter of the American Cancer Society, 
  • an Associate Professor of Clinical and Anatomic Pathology at the University of Nebraska Medical Center, 
  • a Clinical Professor of Pathology at USC’s Keck School of Medicine
  • Senior Medical Reviewer at McKesson / Change Healthcare
  • Chairman of the Board and Chief Executive Officer at Chromavision Medical Systems, Inc.,
  • Chairman and President at Strategic Business Solutions, Inc. (a privately held company specializing in commercialization of biotechnology), 
  • the Medical Director of Native American Tshimakain Creek Cardiometabolic Laboratory
  • Chief Medical Officer of Oncocyte (an oncology diagnostics company), 
  • CEO and Laboratory Director of 
  • Predictive Health Diagnostics
  • Global Discovery Biosciences
  • and Specialty Laboratories, Inc., (related to Nichols Institute and Quest Diagnostics, Inc.), 
  • Laboratory Director, Medical Director, Vice President of Operations, and President of Nichols Institute (now part of Quest Diagnostics), 
  • Principal at Douglas S. Harrington and Associates (a strategic consulting firm), 

and the Founder and CEO of Clarient (a leader in cancer diagnostics).

He currently acts as a managing partner at Cell Rejuvenation Institute, and Chairman, Co-founder, Chief Medical Officer and Chief Science Officer of Smart Health Diagnostics Company, a developer of precision diagnostics that address unmet clinical needs in vascular, metabolic, and oncological diseases using unique evolutionary computational technology, which technology has been successfully applied to 135 projects across 34 diseases.

Other Memberships 

  • American Medical Association 
  • European Society of Cardiology
  • The International Academy of Pathology

Areas of Expertise 

  • Cardiology 
  • Preventive Cardiology
  • Pathology 
  • Hematopathology 
  • Hematology
  • Immunology 
  • Cancer 
  • Functional Medicine
  • Internal Medicine 
  • Preventative Medicine 
  • Tissue Biopsy
  • Fluid Testing 
  • Preventative Wellness

Meet Our Science & Medical Advisory Board

Our Medical Advisory Board is not compensated for their service. They serve, voluntarily, because they believe in our breakthrough technology and use our products with their clients.

HydraStat Technology™

The molecules in many supplements are too large to be absorbed by the cell, so they get excreted from the body without being used effectively. Our water-enveloped, nanosized ingredients are small enough to be fully absorbed into the human cell.

White Paper

Read about the importance of each ingredient combined with our HydraStat Nanotechnology™, and how it's making waves in the industry. Also get insight into our third party testing that ensures each batch is of the highest quality.